Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

Inclusion Criteria

Concurrent Medication:

Allowed:

   - Prophylactic pentamidine for Pneumocystis carinii pneumonia (PCP).

   - Topical steroids.

Patients must:

   - Be HIV positive. Fit one of the zidovudine use groups listed in Disease Status. Be
   able to give informed consent.

Allowed:

   - Basal cell carcinoma of the skin, in situ carcinoma of the cervix, Kaposi's sarcoma.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

   - Major organ allograft.

   - Significant cardiac disease or central nervous system lesions.

   - Known previous intolerance to zidovudine (AZT) at 500 mg/day.

   - Active opportunistic infections. Score of > 0.5 on the ACTG AIDS dementia complex
   staging test. Any focal abnormality on neurologic exam.

Concurrent Medication:

Excluded:

   - Chemotherapy, hormonal therapy, or other immunotherapy.

   - Other investigational drugs, agents, or devices.

   - Beta-blockers.

   - Steroids other than topical.

   - Antihypertensive medication other than diuretics.

Concurrent Treatment:

Excluded:

   - Radiation therapy.

Patients with the following are excluded:

   - History of seizures. Concurrent neoplasms not specifically allowed.

   - Concomitant conditions listed in Exclusion Co-existing Conditions.

Prior Medication:

Excluded within 30 days prior to study entry:

   - Anti-HIV medication other than zidovudine (AZT).

   - Immunomodulators.

   - Systemic steroids.

   - Interferons.

   - Interleukins.

   - Other chemotherapy.

Prior Treatment:

Excluded within 30 days prior to study entry:

   - Radiation therapy.

Excluded within 4 weeks prior to study entry:

   - Groups B, C, D

   - Transfusions.

Active substance abuse.